XML 72 R29.htm IDEA: XBRL DOCUMENT
v3.20.1

Intangible Assets (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Intangible Assets, Net (Excluding Goodwill) [Abstract] |
Schedule of Finite-Lived Intangible Assets | The following table summarizes our intangible assets, net (in millions):
|  | March 31, 2020 |  | December 31, 2019
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (4,428 | ) |  | $ | — |  |  | $ | 6,292 |  |  | $ | 10,720 |  |  | $ | (4,253 | ) |  | $ | — |  |  | $ | 6,467 |
Intangible asset - axicabtagene ciloleucel |  | 6,200 |  |  | (847 | ) |  | — |  |  | 5,353 |  |  | 6,200 |  |  | (761 | ) |  | — |  |  | 5,439 |
Intangible asset - Ranexa |  | 688 |  |  | (688 | ) |  | — |  |  | — |  |  | 688 |  |  | (688 | ) |  | — |  |  | — |
Other |  | 1,098 |  |  | (474 | ) |  | (7 | ) |  | 617 |  |  | 1,098 |  |  | (454 | ) |  | (6 | ) |  | 638 |
Total finite-lived assets |  | 18,706 |  |  | (6,437 | ) |  | (7 | ) |  | 12,262 |  |  | 18,706 |  |  | (6,156 | ) |  | (6 | ) |  | 12,544 |
Indefinite-lived assets - IPR&D |  | 1,247 |  |  | — |  |  | (7 | ) |  | 1,240 |  |  | 1,247 |  |  | — |  |  | (5 | ) |  | 1,242 |
Total intangible assets |  | $ | 19,953 |  |  | $ | (6,437 | ) |  | $ | (14 | ) |  | $ | 13,502 |  |  | $ | 19,953 |  |  | $ | (6,156 | ) |  | $ | (11 | ) |  | $ | 13,786 |
Schedule of Indefinite-Lived Intangible Assets | The following table summarizes our intangible assets, net (in millions):
|  | March 31, 2020 |  | December 31, 2019
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (4,428 | ) |  | $ | — |  |  | $ | 6,292 |  |  | $ | 10,720 |  |  | $ | (4,253 | ) |  | $ | — |  |  | $ | 6,467 |
Intangible asset - axicabtagene ciloleucel |  | 6,200 |  |  | (847 | ) |  | — |  |  | 5,353 |  |  | 6,200 |  |  | (761 | ) |  | — |  |  | 5,439 |
Intangible asset - Ranexa |  | 688 |  |  | (688 | ) |  | — |  |  | — |  |  | 688 |  |  | (688 | ) |  | — |  |  | — |
Other |  | 1,098 |  |  | (474 | ) |  | (7 | ) |  | 617 |  |  | 1,098 |  |  | (454 | ) |  | (6 | ) |  | 638 |
Total finite-lived assets |  | 18,706 |  |  | (6,437 | ) |  | (7 | ) |  | 12,262 |  |  | 18,706 |  |  | (6,156 | ) |  | (6 | ) |  | 12,544 |
Indefinite-lived assets - IPR&D |  | 1,247 |  |  | — |  |  | (7 | ) |  | 1,240 |  |  | 1,247 |  |  | — |  |  | (5 | ) |  | 1,242 |
Total intangible assets |  | $ | 19,953 |  |  | $ | (6,437 | ) |  | $ | (14 | ) |  | $ | 13,502 |  |  | $ | 19,953 |  |  | $ | (6,156 | ) |  | $ | (11 | ) |  | $ | 13,786 |
Schedule of Estimated Future Amortization Expense | The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March 31, 2020 (in millions):
Fiscal Year |  | Amount
2020 (remaining nine months) |  | $ | 844 |
2021 |  | 1,124 |
2022 |  | 1,124 |
2023 |  | 1,124 |
2024 |  | 1,124 |
Thereafter |  | 6,922 |
Total |  | $ | 12,262 |

X
- References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b),(d) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration